<DOC>
	<DOCNO>NCT01098188</DOCNO>
	<brief_summary>This study design evaluate safety , pharmacokinetics preliminary efficacy anti-CD20 monoclonal antibody LFB-R603 patient relapse refractory B-cell chronic lymphocytic leukemia receive least one prior fludarabine-containing regimen .</brief_summary>
	<brief_title>LFB-R603 Dose Finding Patients With Advanced Stage B-Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Signed informed consent Relapsed refractory BCLL least one prior course therapy fludarabine Circulating lymphocytes express CD20 Peripheral blood lymphocyte count &gt; 5,000/µL ECOG performance status ≤ 2 Life expectancy ≥ 3 month Negative blood pregnancy test inclusion woman childbearing potential Medically acceptable method birth control throughout study woman childbearing potential Being consider reliable capable adhere protocol compliant study procedure Covered healthcare insurance Transformation CLL high grade lymphoma Allogeneic stem cell transplantation &lt; 6 month enrolment Prior treatment antiCD20 monoclonal antibody &lt; 6 month enrolment Prior treatment alemtuzumab &lt; 2 month enrolment Treatment IMP participation clinical study within 30 day prior enrolment Known severe anaphylactic hypersensitivity reaction secondary prior exposure murine antibody component LFBR603 Patient prior treatment concomitant medication may interfere interpretation study data Patient concomitant malignancy basal cell carcinoma skin , situ carcinoma cervix breast Patient serious nonmalignant disease , active infection require systemic antibiotic , antifungal antiviral drug physical examination laboratory abnormality , would compromise protocol objective Positive serology HIV , HCV presence HBs Ag Creatinine clearance , calculate accord Cockroft Gault formula &lt; 60 mL/min ALT /or AST level &gt; 1.5 time upper limit normal Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>